Last reviewed · How we verify
Abiraterone acetate escalated dose — Competitive Intelligence Brief
phase 2
CYP17A1 inhibitor
CYP17A1 (17α-hydroxylase/17,20-lyase)
Oncology
Small molecule
Live · refreshed every 30 min
Target snapshot
Abiraterone acetate escalated dose (Abiraterone acetate escalated dose) — Assistance Publique - Hôpitaux de Paris. Abiraterone acetate is a CYP17A1 inhibitor that blocks androgen synthesis, reducing testosterone production to treat androgen-dependent cancers.
Comparator set (6 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Abiraterone acetate escalated dose TARGET | Abiraterone acetate escalated dose | Assistance Publique - Hôpitaux de Paris | phase 2 | CYP17A1 inhibitor | CYP17A1 (17α-hydroxylase/17,20-lyase) | |
| Fuzuloparib , Abiraterone acetate and Prednisone | Fuzuloparib , Abiraterone acetate and Prednisone | Jiangsu HengRui Medicine Co., Ltd. | phase 3 | PARP inhibitor (fuzuloparib) combined with CYP17A1 inhibitor (abiraterone acetate) and glucocorticoid (prednisone) | PARP1/PARP2 (fuzuloparib); CYP17A1 (abiraterone acetate); glucocorticoid receptor (prednisone) | |
| Abiraterone acetate and prednisone | Abiraterone acetate and prednisone | Janssen Research & Development, LLC | phase 3 | CYP17A1 inhibitor (androgen synthesis inhibitor) | CYP17A1 (17α-hydroxylase/17,20-lyase) | |
| Abiraterone Acetate (AA) | Abiraterone Acetate (AA) | Janssen Research & Development, LLC | phase 3 | CYP17A1 inhibitor | CYP17A1 (17α-hydroxylase/17,20-lyase) | |
| Abiraterone with Prednisone or Enzalutamide | Abiraterone with Prednisone or Enzalutamide | Curium US LLC | phase 3 | CYP17A1 inhibitor (abiraterone) + androgen receptor antagonist (enzalutamide) + glucocorticoid (prednisone) | CYP17A1 (abiraterone); androgen receptor (enzalutamide); glucocorticoid receptor (prednisone) | |
| Enzalutamide, Abiraterone | Enzalutamide, Abiraterone | Veru Inc. | phase 3 | Androgen receptor antagonist + CYP17A1 inhibitor combination | Androgen receptor (AR) and CYP17A1 | |
| Abiraterone + Prednisolone/Prednisone | Abiraterone + Prednisolone/Prednisone | AstraZeneca | phase 3 | CYP17A1 inhibitor (androgen synthesis inhibitor) + glucocorticoid | CYP17A1 (17α-hydroxylase/17,20-lyase) |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (CYP17A1 inhibitor class)
- Assistance Publique - Hôpitaux de Paris · 1 drug in this class
- Janssen Research & Development, LLC · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Abiraterone acetate escalated dose CI watch — RSS
- Abiraterone acetate escalated dose CI watch — Atom
- Abiraterone acetate escalated dose CI watch — JSON
- Abiraterone acetate escalated dose alone — RSS
- Whole CYP17A1 inhibitor class — RSS
Cite this brief
Drug Landscape (2026). Abiraterone acetate escalated dose — Competitive Intelligence Brief. https://druglandscape.com/ci/abiraterone-acetate-escalated-dose. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab